36
Participants
Start Date
August 14, 2017
Primary Completion Date
February 25, 2019
Study Completion Date
February 25, 2019
rhLactoferrin
Eligible participants will be provided with Recombinant Human lactoferrin (rhLF) in 250 mg capsules along with detailed instructions for taking the study drug and they will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
Placebo
Eligible participant will be provided with placebo in capsules of 250 mg along with detailed instructions for taking the placebo. Participants will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
Jeremy D. Walston, Baltimore
Collaborators (1)
Ventria Bioscience
INDUSTRY
National Institute on Aging (NIA)
NIH
Johns Hopkins University
OTHER